Exemestane Tablet
NDC Package 0832-0595-30
Package Information
Exemestane tablets is a medication used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. This formulation utilizes a tablet delivery system. Marketed by Upsher-smith Laboratories, Inc., this product is identified by NDC 0832-0595 and is authorized under FDA application ANDA209208.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0832 - Upsher-smith Laboratories, Inc.
- 0832-0595 - Exemestane
- 0832-0595-30 - 30 TABLET in 1 BOTTLE
- 0832-0595 - Exemestane
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0832-0595-30 identifies a specific commercial package of 30 tablet in 1 bottle of Exemestane, a human prescription drug labeled by Upsher-smith Laboratories, Inc.. This tablet is formulated for oral use and contains exemestane as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Upsher-smith Laboratories, Inc. on July 27, 2017. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.
How is this Upsher-smith Laboratories, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00832059530. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.